Tech Center 1600 • Art Units: 1621 1626 1628 1672
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18550996 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | Non-Final OA | Vanderbilt University |
| 18553999 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Non-Final OA | Bristol-Myers Squibb Company |
| 18553988 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18269510 | COMPOUND, COMPOSITION, BIOTISSUE EMBRITTLEMENT AGENT, BIOTISSUE SURFACE DETACHMENT METHOD, AND BIOTISSUE DETACHMENT KIT | Non-Final OA | JUNTENDO EDUCATIONAL FOUNDATION |
| 18438385 | BIFUNCTIONAL CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18608354 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 17548915 | PREVENTION OF PRETERM BIRTH (PTB) BY INHIBITION OF FKBP51 | Final Rejection | UNIVERSITY OF SOUTH FLORIDA |
| 17659274 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS | Non-Final OA | GEORGETOWN UNIVERSITY |
| 18555822 | AGENT FOR PROMOTING LIPID REDUCTION | Non-Final OA | MITSUBISHI GAS CHEMICAL COMPANY, INC. |
| 17522171 | PRESERVATIVE CONTAINING COMPOSITIONS | Final Rejection | Kenvue Brands LLC |
| 18665333 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | Non-Final OA | Qpex Biopharma, Inc. |
| 15733818 | COMPOUNDS FOR THIOL-TRIGGERED COS AND/OR H2S RELEASE AND METHODS OF MAKING AND USING THE SAME | Final Rejection | University of Oregon |
| 17758427 | CICLESONIDE FOR AMELIORATING QUALITY OF LIFE (QOL) IN EQUINES | Final Rejection | Boehringer Ingelheim Vetmedica GmbH |
| 18543991 | SYNERGISTIC MULTIMODAL OPIOID FREE ANALGESIC FORMULATION AND METHODS FOR REDUCED POSTOPERATIVE NAUSEA AND VOMITING, INFLAMMATION, AND ENHANCED POSTOPERATIVE PAIN RELIEF | Final Rejection | Hutchison Health, LLC |
| 18543781 | SYNERGISTIC MULTIMODAL OPIOID FREE ANALGESIC FORMULATION AND METHODS FOR REDUCED POSTOPERATIVE NAUSEA AND VOMITING, INFLAMMATION, AND ENHANCED POSTOPERATIVE PAIN RELIEF | Final Rejection | Hutchison Health, LLC |
| 18069006 | ANALGESIC FORMULATIONS AND METHODS FOR REDUCED POSTOPERATIVE NAUSEA AND VOMITING AND ENHANCED POSTOPERATIVE PAIN RELIEF | Final Rejection | Hutchison Health, LLC |
| 18537308 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | Non-Final OA | OPKO HEALTH, INC. |
| 17308153 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | Final Rejection | MURRAY AND POOLE ENTERPRISES LTD |
| 18566093 | CANNABIDIOL FOR USE IN THE TREATMENT OF PAIN RESULTING FROM AN INDOLEAMINE 2,3-DIOXYGENASE-1 (IDO1) RELATED DISEASE | Non-Final OA | Assistance Publique - Hopitaux de Paris |
| 17432158 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18546875 | SESQUITERPENE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | Non-Final OA | MFC CO., LTD. |
| 18551157 | TREATMENT OF HIDRADENITIS SUPPURATIVA WITH ORISMILAST | Non-Final OA | UNION THERAPEUTICS A/S |
| 18463439 | KRAS INHIBITOR AND PHARMACEUTICAL USES THEREOF | Non-Final OA | RISEN (SUZHOU) PHARMA TECH CO., LTD. |
| 18244773 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS | Final Rejection | Kissei Pharmaceutical Co., Ltd. |
| 18464725 | COMPOSITIONS AND METHODS FOR REVERSING AGE-ASSOCIATED DENDRITIC SPINE LOSS | Non-Final OA | UNIVERSITY OF PITTSBURGH MEDICAL CENTER |
| 18280548 | METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | Non-Final OA | CANWELL BIOTECH LIMITED |
| 18237837 | ADJUVANT THERAPY FOR USE IN PROSTATE CANCER TREATMENT | Non-Final OA | FUND SA |
| 17820692 | REMITTIVE EFFECTS OF TAPINAROF IN THE TREATMENT OF PLAQUE PSORIASIS, ATOPIC DERMATITIS, OR RADIATION DERMATITIS | Non-Final OA | Dermavant Sciences GmbH |
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | Final Rejection | Rush University Medical Center |
| 18324306 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | Non-Final OA | GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, UNIVERSITATS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy